ClinicalTrials.gg
TerminatedNCT04363801DisTinGuishUpdated Oct 9, 2025Results posted

A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

A Phase 2 interventional study of DKN-01 300mg and DKN-01 600mg in Gastric Cancer, Gastric Adenocarcinoma and GastroEsophageal Cancer, sponsored by Leap Therapeutics, Inc.. Terminated at 48 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-09.

Sponsored by Leap Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
experimental treatment will not be more efficacious than its comparator in the primary endpoint of PFS

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
247
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing tislelizumab in Stomach Neoplasms — 20 open to participants now, 24 under way, 5 of them phase 3. tislelizumab · Stomach Neoplasms.

Enrollment
5th of 30
247 · median 52
Started
2020
with 1 other
Phase 2
18 of 30
11 open now
Registered
2nd of 30
by date
Lead sponsor
1 of 30
Leap Therapeutics, Inc.

Among the 30 studies testing tislelizumab in Stomach Neoplasms, this one is the 5th largest by enrollment, is one of 2 that started in 2020, is one of 18 in phase 2, and was the 2nd registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

20 of the 30 studies testing tislelizumab in Stomach Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing tislelizumab in Stomach Neoplasms, or all of them as a file.
02

Study summary

A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Read the detailed description

This is a Phase 2 open-label, multicenter study to be conducted concurrently in 3 Parts (Parts A, B, and C). Approximately 232 patients aged 18 years or older with inoperable, histologically confirmed locally advanced or metastatic Gastric or Gastroesophageal Junction (G/GEJ) adenocarcinoma with measurable disease (RECIST v1.1) requiring therapy will be enrolled in the study. Part A and B are designed to evaluate safety, tolerability, and efficacy of the combination therapy of intravenous (IV) DKN-01 and tislelizumab ± CAPOX in G/GEJ adenocarcinoma patients. Treatment continues in repeating 21-day cycles until patient meets criteria for discontinuation or is no longer deriving clinical benefit. Two doses of DKN-01 will be evaluated in Part B (Part B1 and Part B2). Part C is the open-label, randomized, controlled, 2-arm portion of the study to evaluate the efficacy and safety of tislelizumab + chemotherapy regimen (CAPOX or mFOLFOX6) ± DKN-01 in adult patients with inoperable, histologically confirmed locally advanced or metastatic G/GEJ adenocarcinoma with measurable disease (RECIST v1.1) requiring therapy. Approximately 160 patients will be randomized in a 1:1 ratio to receive either DKN-01 in combination with tislelizumab and chemotherapy regimen (CAPOX or mFOLFOX6) (n=80) or tislelizumab in combination with chemotherapy regimen (CAPOX or mFOLFOX6) (n=80).

03

Conditions studied

  • Gastric Cancer
  • Gastric Adenocarcinoma
  • GastroEsophageal Cancer

Keywords

  • Gastric cancer
  • Gastroesophageal junction
  • cancer
  • adenocarcinoma
  • DKK1
  • Tislelizumab
  • DKN-01
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A \& C:

  1. No previous therapy for cancer. Patients may have received prior or adjuvant therapy as long it was completed without disease recurrence for at least 6 months since last treatment.

    Part B Only:

  2. Disease progression during therapy or within 4 months after the last dose of first-line therapy.
  3. Documentation of elevated Dickkopf-1 (DKK1) messenger ribonucleic acid (mRNA) expression from a fresh tumor or a biopsy obtained within the 6 months of screening.

    Part C Only:

  4. Documentation of programmed cell death protein ligand-1 () combined positive score (CPS) by immunohistochemistry (IHC) and DKK1 mRNA expression in tumor cells by ISH from a fresh tumor biopsy (preferred) or archived tumor biopsy specimen conducted in a Sponsor designated central laboratory.

    General:

  5. Able to provide written prior to any study-specific procedures.
  6. Age ≥18 years on the day of signing the informed consent (exception: ≥19 years in the Republic of Korea).
  7. Confirmed diagnosis of gastric adenocarcinoma or gastroesophageal junction (GEJ) adenocarcinoma.
  8. One or more tumors measurable on radiographic imaging as defined by Response Evaluation Criteria in Solid Tumor () 1.1.
  9. Tumor tissue for mandatory pre-treatment evaluation (fresh biopsy [preferred] or archived specimen).
  10. (ECOG) performance status ≤ 1 within 7 days of first dose of study drug
  11. Acceptable liver, renal, hematologic, and coagulation function
  12. Females of and male partners of female patients must agree to use adequate during the study and for 6 months after their last dose of study drug.
  13. Non-sterile males must be willing to use a highly effective method of birth control for the duration of the study and for at least 6 months after the last dose of study drugs.

Exclusion criteria

Exclusion:

Part A \& C Only:

  1. Diagnosis of -positive G/GEJ adenocarcinoma.
  2. Unable to swallow capsules or disease significantly affected gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction (for those receiving CAPOX in Part C).
  3. Prior therapy with an anti-programmed cell death protein 1 () or anti-PD-L1 antibody.

    Part B Only:

  4. Major surgery or chemotherapy within 21 days of first dose of study drug.

    General:

  5. Squamous cell or undifferentiated or other histological type of gastric cancer.
  6. Prior therapy with an anti-PD-L2 or any other antibody or drug specifically targeting T-cell co-stimulation or co-inhibitory checkpoint pathways in any treatment setting (including /neoadjuvant) or prior therapy with an anti-DKK1 agent.
  7. Patients with active diseases or history of autoimmune diseases that may relapse.
  8. Any condition that required treatment with or any other immune suppressive drugs within 14 days prior to first dose of study drug.
  9. Active or uncontrolled .
  10. Any active cancer ≤ 2 years before first dose of study drug with the exception of cancer for this study.
  11. Uncontrolled diabetes or >Grade 1 laboratory test abnormalities in potassium, sodium, or corrected calcium despite standard medical management or ≥Grade 3 hypoalbuminemia within 14 days before first dose of study drug.
  12. Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage within 7 days prior to first dose of study drug.
  13. anorexia within 7 days prior to first dose of study drug.
  14. History of interstitial lung disease, non-infectious pneumonitis, pulmonary fibrosis, acute lung disease, or uncontrolled systemic diseases.
  15. Active, uncontrolled bacterial, viral, or fungal infections, within 14 days of study entry requiring systemic therapy.
  16. Prior stem cell transplantation or organ transplantation.
  17. History of severe reactions to other monoclonal antibodies or any components of study treatment.
  18. Known dihydropyrimidine dehydrogenase deficiency.
  19. Class III or IV cardiac disease, myocardial infarction within the past 6 months, or unstable arrhythmia.
  20. Fridericia- interval (QTcF) > 470 msec (female) or history of congenital long QT syndrome.
  21. Known to be (HIV) positive.
  22. Serious nonmalignant disease
  23. History of osteonecrosis of the hip or have evidence of structural bone abnormalities in the proximal femur on magnetic resonance imaging (MRI) scan that are symptomatic and clinically significant.
  24. Known osteoblastic bony .
  25. History of gastrointestinal perforation and/or fistulae within 6 months prior to first dose of study drug.
  26. Major surgery 28 days prior to study entry.
  27. Serious psychiatric or medical conditions that could interfere with treatment.
  28. Toxicities (as a result of prior anticancer therapy) that have not recovered to baseline or stabilized, except for Adverse Events (AEs) not considered a likely safety risk (e.g., alopecia, neuropathy, and specific laboratory abnormalities).
  29. Administration of a within 28 days before first dose of study drug.
  30. Active substance abuse.
  31. Pregnant or nursing.
  32. Concurrent participation in another therapeutic clinical study.
  33. Prior radiation therapy within 14 days prior to study entry.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
247 participants (actual)

Study arms

  • Experimental
    Part A First Line Treatment

    Part A patients will receive IV DKN-01 (300 mg) on Days 1 and 15, IV tislelizumab (200 mg) on Day 1, IV oxaliplatin (130 mg/m2) on Day 1, and oral capecitabine (1000 mg/m2 twice daily \[BID\]) on Days 1-15 of each 21-day cycle. Part A is restricted to patients who have not had prior systemic therapy for locally advanced or metastatic disease. Patients may have received prior neoadjuvant or adjuvant therapy as long as it was completed without disease recurrence for at least 6 months.

    Drug: DKN-01 300mg · Drug: DKN-01 400mg · Drug: Tislelizumab 200mg · Drug: Tislelizumab 400mg

  • Experimental
    Part B1 Second Line Treatment

    Part B patients will receive IV DKN-01 (300 mg) on Days 1 and 15 and IV tislelizumab (200 mg) on Day 1 of each 21-day cycle. Patients enrolled in Part B are required to have DKK1-high (H-score ≥ 35) G/GEJ adenocarcinoma (pre-screen biopsy) and must have had only 1 prior systemic therapy for locally advanced/metastatic disease (platinum + fluoropyrimidine-based therapy; ±Human Epidermal growth factor Receptor 2 \[HER2\] therapy if applicable). Patients may have received prior neoadjuvant or adjuvant therapy.

    Drug: DKN-01 300mg · Drug: DKN-01 400mg

  • Experimental
    Part B2 Second Line Treatment

    Part B patients will receive IV DKN-01 (600 mg) on Days 1 and 15 and IV tislelizumab (200 mg) on Day 1 of each 21-day cycle. Patients enrolled in Part B are required to have DKK1-high (H-score ≥ 35) G/GEJ adenocarcinoma (pre-screen biopsy) and must have had only 1 prior systemic therapy for locally advanced/metastatic disease (platinum + fluoropyrimidine-based therapy; ±HER2 therapy if applicable). Patients may have received prior neoadjuvant or adjuvant therapy.

    Drug: DKN-01 600mg · Drug: DKN-01 400mg

  • Active comparator
    Part C Control First Line Treatment

    Part C control patients will receive only tislelizumab in combination with chemotherapy regimen (CAPOX or mFOLFOX6). Part C is restricted to patients who have not had prior systemic therapy for locally advanced or metastatic disease. Patients may have received prior neoadjuvant or adjuvant therapy as long as it was completed without disease recurrence for at least 6 months.

    Drug: Tislelizumab 200mg · Drug: Tislelizumab 400mg · Drug: Oxaliplatin · Drug: Capecitabine 1000mg/ m2 twice daily (BID) · Drug: Leucovorin Calcium · Drug: Fluorouracil

  • Experimental
    Part C Experimental First Line Treatment

    Part C experimental patients will receive DKN-01 in combination with tislelizumab and chemotherapy regimen (CAPOX or mFOLFOX6). Part C is restricted to patients who have not had prior systemic therapy for locally advanced or metastatic disease. Patients may have received prior neoadjuvant or adjuvant therapy as long as it was completed without disease recurrence for at least 6 months.

    Drug: DKN-01 600mg · Drug: DKN-01 400mg · Drug: Tislelizumab 200mg · Drug: Tislelizumab 400mg · Drug: Oxaliplatin · Drug: Capecitabine 1000mg/ m2 twice daily (BID) · Drug: Leucovorin Calcium · Drug: Fluorouracil

Interventions

  • Administered by IV infusion

    Also known as: Experimental

  • Administered by IV infusion

    Also known as: Experimental

  • Administered by IV infusion

    Also known as: Experimental

  • Administered by IV infusion

    Also known as: humanized IgG4 anti-PD-1 monoclonal antibody, Tevimbra

  • Administered by IV infusion

    Also known as: humanized IgG4 anti-PD-1 monoclonal antibody, Tevimbra

  • Administered by IV infusion

    Also known as: Eloxatin

  • DrugCapecitabine 1000mg/ m2 twice daily (BID)

    Drug page: Capecitabine

    Administered orally

    Also known as: Xeloda

  • Administered by IV infusion

    Also known as: Folinic acid

  • Administered by IV infusion

    Also known as: 5-FU

06

What researchers measure

Primary outcomes

  1. Part A and B: Safety and Tolerability of DKN-01 in G/GEJ Patients

    Number of subjects with adverse drug reactions and toxicities as assessed by CTCAE v5.0 CAPOX (capecitabine + oxaliplatin) in patients with inoperable, locally advanced or metastatic G/GEJ adenocarcinoma.

    Time frame: approximately 28 months

  2. Part C: Progression Free Survival (PFS) in G/GEJ DKK1 High and Overall Patients Treated With DKN-01 in Combination With Tislelizumab and Chemotherapy vs Tislelizumab and Chemotherapy as a First-line Therapy

    PFS was measured from the date of randomization to the date of documented disease progression, based on investigator assessed radiologic review using RECIST v1.1, or death due to any cause, whichever occurred first. If the patient had not died, but there was no radiographic post-baseline tumor assessment, PFS was censored at the date of randomization. If there were radiographic post-baseline tumor assessments that verified lack of disease progression, PFS was censored at the most recent tumor assessment before the data cut-off or study withdrawal, whichever occurred first.

    Time frame: approximately 30 months

Secondary outcomes

  1. Part A: Objective Response Rate (ORR) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab + CAPOX as a First-line Therapy

    Objective Response Rate (ORR) is defined as the proportion of patients achieving best overall response of Complete Response (CR) or Partial Response (PR) through radiological assessment of tumor response, based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Investigators were urged to have the same radiographic imaging modality used throughout the study for each subject (at baseline and at subsequent assessments) in order to provide uniformity of radiographic assessments.

    Time frame: approximately 28 months

  2. Part B: Objective Response Rate (ORR) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy

    Objective Response Rate (ORR) is defined as the proportion of patients achieving best overall response of Complete Response (CR) or Partial Response (PR) as assessed with Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).

    Time frame: approximately 28 months

  3. Part A: Duration of Response (DoR) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy

    DoR is defined only for responders (patients with BOR of CR or PR) as the time from initial response until radiographically documented progressive disease or death due to any cause, whichever is earlier.

    Time frame: approximately 28 months

  4. Part A: Duration of Complete Response (DoCR) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy

    DoCR is defined as the time from initial complete response (CR) until radiographically documented progressive disease or death due to any cause, whichever is first.

    Time frame: approximately 28 months

  5. Part A: Progression Free Survival (PFS) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy

    For RECIST, PFS is defined as the time from first study drug dose (i.e., C1D1) to first radiographically documented progressive disease or death due to any cause.

    Time frame: approximately 28 months

  6. Part A: Overall Survival (OS) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy

    Overall survival (OS) is defined as the time from first study drug dose (i.e., C1D1) to first radiographically documented progressive disease or death due to any cause.

    Time frame: approximately 28 months

  7. Part A: Duration of Clinical Benefit (DoCB) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy

    DoCB is defined as the time from the initiation of DKN-01 to the time of progressive disease or death due to any cause, whichever occurs first, for patients who had a BOR of CR, PR, or SD of ≥6 weeks.

    Time frame: approximately 28 months

  8. Part A: Durable Clinical Benefit (DCB) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy

    Durable clinical benefit (DCB) is defined as the proportion of patients presenting a Duration of clinical benefit (DoCB) for ≥180 days from initiation of DKN-01. Patients who have a best overall response of PD or those with clinical benefit lasting \<180 days are not included.

    Time frame: approximately 28 months

  9. Part A: Disease Control Rate (DCR) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy

    DCR is defined as the proportion of patients presenting with a best overall response (BOR) of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) for a duration of at least 6 weeks from initiation of DKN-01, as assessed by the Investigator using RECIST v1.1.

    Time frame: approximately 28 months

  10. Part B: Duration of Response (DoR) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy

    DoR is defined only for responders (patients with BOR of CR or PR) as the time from initial response until radiographically documented progressive disease or death due to any cause, whichever is earlier.

    Time frame: approximately 28 months

  11. Part B: Duration of Complete Response (DoCR) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy

    Duration of complete response (DoCR) is defined as the time from initial CR until radiographically documented progressive disease or death due to any cause, whichever is first. No patients had a complete response (CR); therefore, the DoCR was not applicable.

    Time frame: approximately 28 months

  12. Part B: Progression Free Survival (PFS) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy

    For RECIST, PFS is defined as the time from first study drug dose (i.e., C1D1) to first radiographically documented progressive disease or death due to any cause.

    Time frame: approximately 28 months

  13. Part B: Overall Survival (OS) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy

    Overall survival (OS) is defined as the time from first study drug dose (i.e., C1D1) to first radiographically documented progressive disease or death due to any cause.

    Time frame: approximately 28 months

  14. Part B: Duration of Clinical Benefit (DoCB) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy

    Duration of clinical benefit (DoCB) is defined as the time from the initiation of DKN-01 to the time of progressive disease or death due to any cause, whichever occurs first, for patients who had a BOR of CR, PR, or SD of ≥6 weeks.

    Time frame: approximately 28 months

  15. Part B: Durable Clinical Benefit (DCB) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy

    DCB rate is defined as the proportion of patients presenting a DoCB (Duration of clinical benefit) for ≥ 180 days from initiation of DKN-01, Patients who have a best overall response of PD or those with clinical benefit lasting \<180 days will not be included.

    Time frame: approximately 28 months

  16. Part B: Disease Control Rate (DCR) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy

    DCR is defined as the proportion of patients presenting with a best overall response (BOR) of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) for a duration of at least 6 weeks from initiation of DKN-01, as assessed by the Investigator using RECIST v1.1.

    Time frame: approximately 28 months

  17. Part C: To Estimate the Objective Response Rate (ORR) in DKK1-high G/GEJ Adenocarcinoma Patients Treated With DKN-01 in Combination With Tislelizumab + Chemotherapy Regimen (CAPOX or mFOLFOX6) as a First-line Therapy.

    Objective Response Rate (ORR) is defined as the proportion of patients achieving best overall response of Complete Response (CR) or Partial Response (PR) as assessed by the investigator using RECIST v1.1. Experimental group: Sirexatamab + tislelizumab + CAPOX/FOLFOX, Control group: Tislelizumab + CAPOX/FOLFOX

    Time frame: approximately 30 months

  18. Part C: To Estimate the Duration of Response (DoR) in DKK1-high G/GEJ Adenocarcinoma Patients Treated With DKN-01 in Combination With Tislelizumab + Chemotherapy Regimen (CAPOX or mFOLFOX6) as a First-line Therapy.

    The duration of response (DoR) is defined only for responders (patients with a BOR of CR or PR) at the time from initial response (CR or PR) until radiographically documented progressive disease or death due to any cause, whichever is earlier. For ORR patient without PD or death, DoR is censored at the most recent tumor assessment before the data cutoff or study withdrawal, whichever occurs first.

    Time frame: approximately 30 months

  19. Part C: To Estimate the Overall Survival (OS) in DKK1-high G/GEJ Adenocarcinoma Patients Treated With DKN-01 in Combination With Tislelizumab + Chemotherapy Regimen (CAPOX or mFOLFOX6) as a First-line Therapy.

    Overall survival (OS) OS is defined as the time from the date of randomization to death due to any cause. For a patient who is not known to have died by the end of study follow-up, observation of OS is censored at the date the patient was last known to be alive (i.e., date of last contact). Patients lacking data beyond the day of randomization is censored at the date of randomization (i.e., OS duration of 1 day).

    Time frame: approximately 30 months

  20. Part C: Assess Whether the Addition of DKN-01 With Tislelizumab + Chemotherapy Regimen (CAPOX or mFOLFOX6) Improves PFS in Patients w/ Combined Positive Score (CPS) ≥5 or CPS <5 Advanced DKK1-high and Overall G/GEJ Adenocarcinoma as a First-line Therapy.

    PFS was measured from the date of randomization to the date of documented disease progression, based on investigator assessed radiologic review using RECIST v1.1, or death due to any cause, whichever occurred first. If the patient had not died, but there was no radiographic post-baseline tumor assessment, PFS was censored at the date of randomization. If there were radiographic post-baseline tumor assessments that verified lack of disease progression, PFS was censored at the most recent tumor assessment before the data cut-off or study withdrawal, whichever occurred first.

    Time frame: approximately 30 months

  21. Part C: To Assess Whether the Addition of DKN-01 With Tislelizumab + Chemotherapy Regimen (CAPOX or mFOLFOX6) Improves ORR in Patients With CPS ≥5 or CPS <5 Advanced DKK1-high and Overall G/GEJ Adenocarcinoma as a First-line Therapy.

    Objective Response Rate (ORR) is defined as the proportion of patients achieving best overall response of Complete Response (CR) or Partial Response (PR) as assessed by the investigator using RECIST v1.1. Risk difference (RD)(%) or ORR: Positive RD implies the exposure is associated with a higher probability of the outcome occurring. Negative RD indicates the exposure is associated with a lower probability of the outcome occurring.

    Time frame: approximately 30 months

  22. Part C: Number of Patients With Toxicity ≥Grade 3 Treatment-related Adverse Events (TRAE) Associated With Each of the Treatment Arms.

    To characterize the frequency of toxicity ≥Grade 3 treatment-related adverse events (TRAE) associated with each treatment arm: Control (tislelizumab in combination with chemotherapy regimen (CAPOX or mFOLFOX6) and Experimental (DKN-01 in combination with tislelizumab and chemotherapy regimen (CAPOX or mFOLFOX6))

    Time frame: approximately 30 months

07

Results

Posted Oct 9, 2025
Limitations and caveats
The study was terminated prematurely due to lack of efficacy. Therefore, only limited efficacy analyses were performed on the primary and limited secondary efficacy endpoints. Parts A+B were initiated and completed. Part C was initiated upon completion of Parts A+B. Due to termination of the program during Part C, combined analysis for Parts A+B and C was not performed.

Participant flow

This was a Phase 2 open-label, multicenter study conducted concurrently in 3 parts: Non-randomized Parts A and B, and a randomized Part C.

Participant flow — Overall Study
MilestonePart A First Line TreatmentPart B1 Second Line TreatmentPart B2 Second Line TreatmentPart C Control First Line TreatmentPart C Experimental First Line Treatment
Started2524288585
Completed00000
Not completed2524288585
Withdrew: Death1814164838
Withdrew: Withdrawal by subject161414
Withdrew: Sponsor decision64103332
Withdrew: Lost to follow-up00101

Outcome measures

PrimaryPart A and B: Safety and Tolerability of DKN-01 in G/GEJ Patients

Number of subjects with adverse drug reactions and toxicities as assessed by CTCAE v5.0 CAPOX (capecitabine + oxaliplatin) in patients with inoperable, locally advanced or metastatic G/GEJ adenocarcinoma.

Time frame:
approximately 28 months
Reported as:
Count of participants · Participants
Part A and B: Safety and Tolerability of DKN-01 in G/GEJ Patients
ParticipantsPart A First Line TreatmentPart B1 Second Line TreatmentPart B2 Second Line Treatment
Part A and B: Safety and Tolerability of DKN-01 in G/GEJ Patients252425
PrimaryPart C: Progression Free Survival (PFS) in G/GEJ DKK1 High and Overall Patients Treated With DKN-01 in Combination With Tislelizumab and Chemotherapy vs Tislelizumab and Chemotherapy as a First-line Therapy

PFS was measured from the date of randomization to the date of documented disease progression, based on investigator assessed radiologic review using RECIST v1.1, or death due to any cause, whichever occurred first. If the patient had not died, but there was no radiographic post-baseline tumor assessment, PFS was censored at the date of randomization. If there were radiographic post-baseline tumor assessments that verified lack of disease progression, PFS was censored at the most recent tumor assessment before the data cut-off or study withdrawal, whichever occurred first.

Time frame:
approximately 30 months
Reported as:
Median · Months
Part C: Progression Free Survival (PFS) in G/GEJ DKK1 High and Overall Patients Treated With DKN-01 in Combination With Tislelizumab and Chemotherapy vs Tislelizumab and Chemotherapy as a First-line Therapy
MonthsPart C Control First Line TreatmentPart C Experimental First Line Treatment
Part C: Progression Free Survival (PFS) in G/GEJ DKK1 High and Overall Patients Treated With DKN-01 in Combination With Tislelizumab and Chemotherapy vs Tislelizumab and Chemotherapy as a First-line Therapy10.41 (7.75 to 13.86)7.66 (6.87 to 9.49)
Statistical analysis
  • Part C Control First Line Treatment vs Part C Experimental First Line Treatment · Log Rank · p = 0.9676 · Hazard ratio (hr): 1.42 · 95% CI 0.98 to 2.05
SecondaryPart A: Objective Response Rate (ORR) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab + CAPOX as a First-line Therapy

Objective Response Rate (ORR) is defined as the proportion of patients achieving best overall response of Complete Response (CR) or Partial Response (PR) through radiological assessment of tumor response, based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Investigators were urged to have the same radiographic imaging modality used throughout the study for each subject (at baseline and at subsequent assessments) in order to provide uniformity of radiographic assessments.

Time frame:
approximately 28 months
Reported as:
Number · percentage of patients
Part A: Objective Response Rate (ORR) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab + CAPOX as a First-line Therapy
percentage of patientsPart A First Line Treatment
Part A: Objective Response Rate (ORR) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab + CAPOX as a First-line Therapy72.7 (49.8 to 89.3)
SecondaryPart B: Objective Response Rate (ORR) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy

Objective Response Rate (ORR) is defined as the proportion of patients achieving best overall response of Complete Response (CR) or Partial Response (PR) as assessed with Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).

Time frame:
approximately 28 months
Reported as:
Number · percentage of patients
Part B: Objective Response Rate (ORR) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy
percentage of patientsPart B1 Second Line TreatmentPart B2 Second Line Treatment
Part B: Objective Response Rate (ORR) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy18.2 (5.19 to 40.3)25.0 (9.77 to 46.7)
SecondaryPart A: Duration of Response (DoR) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy

DoR is defined only for responders (patients with BOR of CR or PR) as the time from initial response until radiographically documented progressive disease or death due to any cause, whichever is earlier.

Time frame:
approximately 28 months
Reported as:
Median · months
Part A: Duration of Response (DoR) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy
monthsPart A First Line Treatment
Part A: Duration of Response (DoR) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy10.0 (5.1 to 19.2)
SecondaryPart A: Duration of Complete Response (DoCR) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy

DoCR is defined as the time from initial complete response (CR) until radiographically documented progressive disease or death due to any cause, whichever is first.

Time frame:
approximately 28 months
Reported as:
Median · months
Part A: Duration of Complete Response (DoCR) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy
monthsPart A First Line Treatment
Part A: Duration of Complete Response (DoCR) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy12.7 (NA to NA)
SecondaryPart A: Progression Free Survival (PFS) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy

For RECIST, PFS is defined as the time from first study drug dose (i.e., C1D1) to first radiographically documented progressive disease or death due to any cause.

Time frame:
approximately 28 months
Reported as:
Median · Months
Part A: Progression Free Survival (PFS) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy
MonthsPart A First Line Treatment
Part A: Progression Free Survival (PFS) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy11.8 (7.9 to NA)
SecondaryPart A: Overall Survival (OS) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy

Overall survival (OS) is defined as the time from first study drug dose (i.e., C1D1) to first radiographically documented progressive disease or death due to any cause.

Time frame:
approximately 28 months
Reported as:
Median · months
Part A: Overall Survival (OS) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy
monthsPart A First Line Treatment
Part A: Overall Survival (OS) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy19.7 (15.3 to NA)
SecondaryPart A: Duration of Clinical Benefit (DoCB) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy

DoCB is defined as the time from the initiation of DKN-01 to the time of progressive disease or death due to any cause, whichever occurs first, for patients who had a BOR of CR, PR, or SD of ≥6 weeks.

Time frame:
approximately 28 months
Reported as:
Median · months
Part A: Duration of Clinical Benefit (DoCB) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy
monthsPart A First Line Treatment
Part A: Duration of Clinical Benefit (DoCB) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy11.9 (8.2 to NA)
SecondaryPart A: Durable Clinical Benefit (DCB) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy

Durable clinical benefit (DCB) is defined as the proportion of patients presenting a Duration of clinical benefit (DoCB) for ≥180 days from initiation of DKN-01. Patients who have a best overall response of PD or those with clinical benefit lasting \<180 days are not included.

Time frame:
approximately 28 months
Reported as:
Number · percentage of patients
Part A: Durable Clinical Benefit (DCB) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy
percentage of patientsPart A First Line Treatment
Part A: Durable Clinical Benefit (DCB) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy72.7 (49.8 to 89.3)
SecondaryPart A: Disease Control Rate (DCR) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy

DCR is defined as the proportion of patients presenting with a best overall response (BOR) of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) for a duration of at least 6 weeks from initiation of DKN-01, as assessed by the Investigator using RECIST v1.1.

Time frame:
approximately 28 months
Reported as:
Number · percentage of patients
Part A: Disease Control Rate (DCR) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy
percentage of patientsPart A First Line Treatment
Part A: Disease Control Rate (DCR) in G/GEJ Patients Treated With DKN-01 With Tislelizumab + CAPOX as a First-line Therapy95.5 (77.2 to 99.9)
SecondaryPart B: Duration of Response (DoR) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy

DoR is defined only for responders (patients with BOR of CR or PR) as the time from initial response until radiographically documented progressive disease or death due to any cause, whichever is earlier.

Time frame:
approximately 28 months
Reported as:
Median · months
Part B: Duration of Response (DoR) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy
monthsPart B1 Second Line TreatmentPart B2 Second Line Treatment
Part B: Duration of Response (DoR) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line TherapyNA (1.5 to NA)5.6 (2.3 to NA)
SecondaryPart B: Duration of Complete Response (DoCR) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy

Duration of complete response (DoCR) is defined as the time from initial CR until radiographically documented progressive disease or death due to any cause, whichever is first. No patients had a complete response (CR); therefore, the DoCR was not applicable.

Time frame:
approximately 28 months

Results for this outcome have not been posted.

SecondaryPart B: Progression Free Survival (PFS) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy

For RECIST, PFS is defined as the time from first study drug dose (i.e., C1D1) to first radiographically documented progressive disease or death due to any cause.

Time frame:
approximately 28 months
Reported as:
Median · months
Part B: Progression Free Survival (PFS) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy
monthsPart B1 Second Line TreatmentPart B2 Second Line Treatment
Part B: Progression Free Survival (PFS) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy1.4 (1.3 to 2.3)1.4 (1.2 to 6.8)
SecondaryPart B: Overall Survival (OS) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy

Overall survival (OS) is defined as the time from first study drug dose (i.e., C1D1) to first radiographically documented progressive disease or death due to any cause.

Time frame:
approximately 28 months
Reported as:
Median · months
Part B: Overall Survival (OS) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy
monthsPart B1 Second Line TreatmentPart B2 Second Line Treatment
Part B: Overall Survival (OS) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy8.2 (2.6 to 18.0)7.7 (3.8 to NA)
SecondaryPart B: Duration of Clinical Benefit (DoCB) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy

Duration of clinical benefit (DoCB) is defined as the time from the initiation of DKN-01 to the time of progressive disease or death due to any cause, whichever occurs first, for patients who had a BOR of CR, PR, or SD of ≥6 weeks.

Time frame:
approximately 28 months
Reported as:
Median · months
Part B: Duration of Clinical Benefit (DoCB) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy
monthsPart B1 Second Line TreatmentPart B2 Second Line Treatment
Part B: Duration of Clinical Benefit (DoCB) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line TherapyNA (11.8 to NA)NA (6.8 to NA)
SecondaryPart B: Durable Clinical Benefit (DCB) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy

DCB rate is defined as the proportion of patients presenting a DoCB (Duration of clinical benefit) for ≥ 180 days from initiation of DKN-01, Patients who have a best overall response of PD or those with clinical benefit lasting \<180 days will not be included.

Time frame:
approximately 28 months
Reported as:
Number · percentage of patients
Part B: Durable Clinical Benefit (DCB) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy
percentage of patientsPart B1 Second Line TreatmentPart B2 Second Line Treatment
Part B: Durable Clinical Benefit (DCB) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy18.2 (5.19 to 40.3)33.3 (15.6 to 55.3)
SecondaryPart B: Disease Control Rate (DCR) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy

DCR is defined as the proportion of patients presenting with a best overall response (BOR) of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) for a duration of at least 6 weeks from initiation of DKN-01, as assessed by the Investigator using RECIST v1.1.

Time frame:
approximately 28 months
Reported as:
Number · percentage of patients
Part B: Disease Control Rate (DCR) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy
percentage of patientsPart B1 Second Line TreatmentPart B2 Second Line Treatment
Part B: Disease Control Rate (DCR) in G/GEJ Patients Treated With DKN-01 in Combination With Tislelizumab as a Second-line Therapy31.8 (13.9 to 54.9)37.5 (18.8 to 59.4)
SecondaryPart C: To Estimate the Objective Response Rate (ORR) in DKK1-high G/GEJ Adenocarcinoma Patients Treated With DKN-01 in Combination With Tislelizumab + Chemotherapy Regimen (CAPOX or mFOLFOX6) as a First-line Therapy.

Objective Response Rate (ORR) is defined as the proportion of patients achieving best overall response of Complete Response (CR) or Partial Response (PR) as assessed by the investigator using RECIST v1.1. Experimental group: Sirexatamab + tislelizumab + CAPOX/FOLFOX, Control group: Tislelizumab + CAPOX/FOLFOX

Time frame:
approximately 30 months
Reported as:
Number · percentage of patients
Part C: To Estimate the Objective Response Rate (ORR) in DKK1-high G/GEJ Adenocarcinoma Patients Treated With DKN-01 in Combination With Tislelizumab + Chemotherapy Regimen (CAPOX or mFOLFOX6) as a First-line Therapy.
percentage of patientsPart C Control First Line TreatmentPart C Experimental First Line Treatment
Part C: To Estimate the Objective Response Rate (ORR) in DKK1-high G/GEJ Adenocarcinoma Patients Treated With DKN-01 in Combination With Tislelizumab + Chemotherapy Regimen (CAPOX or mFOLFOX6) as a First-line Therapy.57.6 (46.4 to 68.3)60 (48.8 to 70.5)
Statistical analysis
  • Part C Control First Line Treatment vs Part C Experimental First Line Treatment · Cochran-Mantel-Haenszel · p = 0.3799 · Risk difference (rd): 2.4 · 95% CI -12.2 to 16.9
SecondaryPart C: To Estimate the Duration of Response (DoR) in DKK1-high G/GEJ Adenocarcinoma Patients Treated With DKN-01 in Combination With Tislelizumab + Chemotherapy Regimen (CAPOX or mFOLFOX6) as a First-line Therapy.

The duration of response (DoR) is defined only for responders (patients with a BOR of CR or PR) at the time from initial response (CR or PR) until radiographically documented progressive disease or death due to any cause, whichever is earlier. For ORR patient without PD or death, DoR is censored at the most recent tumor assessment before the data cutoff or study withdrawal, whichever occurs first.

Time frame:
approximately 30 months
Reported as:
Median · months
Part C: To Estimate the Duration of Response (DoR) in DKK1-high G/GEJ Adenocarcinoma Patients Treated With DKN-01 in Combination With Tislelizumab + Chemotherapy Regimen (CAPOX or mFOLFOX6) as a First-line Therapy.
monthsPart C Control First Line TreatmentPart C Experimental First Line Treatment
Part C: To Estimate the Duration of Response (DoR) in DKK1-high G/GEJ Adenocarcinoma Patients Treated With DKN-01 in Combination With Tislelizumab + Chemotherapy Regimen (CAPOX or mFOLFOX6) as a First-line Therapy.12.06 (7.56 to 16.99)6.24 (5.06 to 8.54)
SecondaryPart C: To Estimate the Overall Survival (OS) in DKK1-high G/GEJ Adenocarcinoma Patients Treated With DKN-01 in Combination With Tislelizumab + Chemotherapy Regimen (CAPOX or mFOLFOX6) as a First-line Therapy.

Overall survival (OS) OS is defined as the time from the date of randomization to death due to any cause. For a patient who is not known to have died by the end of study follow-up, observation of OS is censored at the date the patient was last known to be alive (i.e., date of last contact). Patients lacking data beyond the day of randomization is censored at the date of randomization (i.e., OS duration of 1 day).

Time frame:
approximately 30 months
Reported as:
Median · months
Part C: To Estimate the Overall Survival (OS) in DKK1-high G/GEJ Adenocarcinoma Patients Treated With DKN-01 in Combination With Tislelizumab + Chemotherapy Regimen (CAPOX or mFOLFOX6) as a First-line Therapy.
monthsPart C Control First Line TreatmentPart C Experimental First Line Treatment
Part C: To Estimate the Overall Survival (OS) in DKK1-high G/GEJ Adenocarcinoma Patients Treated With DKN-01 in Combination With Tislelizumab + Chemotherapy Regimen (CAPOX or mFOLFOX6) as a First-line Therapy.18.76 (14.00 to NA)15.38 (13.40 to 19.45)
SecondaryPart C: Assess Whether the Addition of DKN-01 With Tislelizumab + Chemotherapy Regimen (CAPOX or mFOLFOX6) Improves PFS in Patients w/ Combined Positive Score (CPS) ≥5 or CPS <5 Advanced DKK1-high and Overall G/GEJ Adenocarcinoma as a First-line Therapy.

PFS was measured from the date of randomization to the date of documented disease progression, based on investigator assessed radiologic review using RECIST v1.1, or death due to any cause, whichever occurred first. If the patient had not died, but there was no radiographic post-baseline tumor assessment, PFS was censored at the date of randomization. If there were radiographic post-baseline tumor assessments that verified lack of disease progression, PFS was censored at the most recent tumor assessment before the data cut-off or study withdrawal, whichever occurred first.

Time frame:
approximately 30 months
Reported as:
Median · Months
Part C: Assess Whether the Addition of DKN-01 With Tislelizumab + Chemotherapy Regimen (CAPOX or mFOLFOX6) Improves PFS in Patients w/ Combined Positive Score (CPS) ≥5 or CPS <5 Advanced DKK1-high and Overall G/GEJ Adenocarcinoma as a First-line Therapy.
MonthsPFS DKK1-high Patients, Part C ExperimentalPFS DKK1-high Patients, Part C ControlPFS All Patients, Part C ExperimentalPFS All Patients, Part C Control
Part C: Assess Whether the Addition of DKN-01 With Tislelizumab + Chemotherapy Regimen (CAPOX or mFOLFOX6) Improves PFS in Patients w/ Combined Positive Score (CPS) ≥5 or CPS <5 Advanced DKK1-high and Overall G/GEJ Adenocarcinoma as a First-line Therapy.7.43 (5.65 to 7.75)11.14 (7.46 to 14.42)7.66 (6.87 to 9.49)10.41 (7.75 to 13.86)
Statistical analysis
  • PFS DKK1-high Patients, Part C Experimental vs PFS DKK1-high Patients, Part C Control · Log Rank · p = 0.8679Stratified Log-rank Test
  • PFS All Patients, Part C Experimental vs PFS All Patients, Part C Control · Log Rank · p = 0.9676Stratified Log-rank Test
  • PFS DKK1-high Patients, Part C Experimental vs PFS DKK1-high Patients, Part C Control · Hazard ratio (hr): 1.50 · 95% CI 0.74 to 3.05
  • PFS All Patients, Part C Experimental vs PFS All Patients, Part C Control · Hazard ratio (hr): 1.42 · 95% CI 0.98 to 2.05
SecondaryPart C: To Assess Whether the Addition of DKN-01 With Tislelizumab + Chemotherapy Regimen (CAPOX or mFOLFOX6) Improves ORR in Patients With CPS ≥5 or CPS <5 Advanced DKK1-high and Overall G/GEJ Adenocarcinoma as a First-line Therapy.

Objective Response Rate (ORR) is defined as the proportion of patients achieving best overall response of Complete Response (CR) or Partial Response (PR) as assessed by the investigator using RECIST v1.1. Risk difference (RD)(%) or ORR: Positive RD implies the exposure is associated with a higher probability of the outcome occurring. Negative RD indicates the exposure is associated with a lower probability of the outcome occurring.

Time frame:
approximately 30 months
Reported as:
Number · percentage
Part C: To Assess Whether the Addition of DKN-01 With Tislelizumab + Chemotherapy Regimen (CAPOX or mFOLFOX6) Improves ORR in Patients With CPS ≥5 or CPS <5 Advanced DKK1-high and Overall G/GEJ Adenocarcinoma as a First-line Therapy.
percentageORR DKK1-high Patients, Part C ExperimentalORR DKK1-high Patient, Part C ControlORR All Patients, Part C ExperimentalORR All Patients, Part C Control
Part C: To Assess Whether the Addition of DKN-01 With Tislelizumab + Chemotherapy Regimen (CAPOX or mFOLFOX6) Improves ORR in Patients With CPS ≥5 or CPS <5 Advanced DKK1-high and Overall G/GEJ Adenocarcinoma as a First-line Therapy.72.7 (49.8 to 89.3)63.6 (40.7 to 82.8)60 (48.8 to 70.5)57.6 (46.4 to 68.3)
Statistical analysis
  • ORR DKK1-high Patients, Part C Experimental vs ORR DKK1-high Patient, Part C Control · Mantel Haenszel · p = 0.2649 · Risk difference (rd): 8.4 · 95% CI -18.4 to 33.6Common Risk Difference and 95% CI: estimated by stratified Newcombe method, weighted by minimum risk
  • ORR All Patients, Part C Experimental vs ORR All Patients, Part C Control · Mantel Haenszel · p = 0.379 · Risk difference (rd): 2.4 · 95% CI -12.2 to 16.9
SecondaryPart C: Number of Patients With Toxicity ≥Grade 3 Treatment-related Adverse Events (TRAE) Associated With Each of the Treatment Arms.

To characterize the frequency of toxicity ≥Grade 3 treatment-related adverse events (TRAE) associated with each treatment arm: Control (tislelizumab in combination with chemotherapy regimen (CAPOX or mFOLFOX6) and Experimental (DKN-01 in combination with tislelizumab and chemotherapy regimen (CAPOX or mFOLFOX6))

Time frame:
approximately 30 months
Reported as:
Number · number of patients
Part C: Number of Patients With Toxicity ≥Grade 3 Treatment-related Adverse Events (TRAE) Associated With Each of the Treatment Arms.
number of patientsPart C Control First Line TreatmentPart C Experimental First Line Treatment
Part C: Number of Patients With Toxicity ≥Grade 3 Treatment-related Adverse Events (TRAE) Associated With Each of the Treatment Arms.5357

Adverse events

Collected over Up to 30 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A First Line Treatment18/25 (72%)11/25 (44%)25/25 (100%)
Part B1 Second Line Treatment14/24 (58.3%)13/24 (54.2%)23/24 (95.8%)
Part B2 Second Line Treatment16/28 (57.1%)13/28 (46.4%)24/28 (85.7%)
Part C Control First Line Treatment48/85 (56.5%)33/85 (38.8%)82/85 (96.5%)
Part C Experimental First Line Treatment38/85 (44.7%)37/85 (43.5%)83/85 (97.6%)
Most frequent serious events
Showing 10 of 93
Most frequent serious events
EventPart A First Line TreatmentPart B1 Second Line TreatmentPart B2 Second Line TreatmentPart C Control First Line TreatmentPart C Experimental First Line Treatment
Abdominal painGastrointestinal disorders0/253/244/280/852/85
VomitingGastrointestinal disorders1/252/240/280/852/85
PyrexiaGeneral disorders2/251/241/286/853/85
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/250/240/281/850/85
Biliary obstructionHepatobiliary disorders0/250/242/280/850/85
Acute kidney injuryRenal and urinary disorders1/250/240/285/851/85
Obstruction gastricGastrointestinal disorders0/251/240/280/854/85
Hypoaesthesia oralGastrointestinal disorders0/251/240/280/850/85
NauseaGastrointestinal disorders0/251/240/282/851/85
FatigueGeneral disorders0/251/241/281/850/85
Most frequent other events
Showing 10 of 400
Most frequent other events
EventPart A First Line TreatmentPart B1 Second Line TreatmentPart B2 Second Line TreatmentPart C Control First Line TreatmentPart C Experimental First Line Treatment
NauseaGastrointestinal disorders19/257/245/2827/8531/85
DiarrhoeaGastrointestinal disorders18/254/240/2823/8523/85
FatigueGeneral disorders17/257/246/2823/8525/85
ConstipationGastrointestinal disorders12/255/241/2830/8521/85
VomitingGastrointestinal disorders11/253/242/2817/8522/85
Peripheral sensory neuropathyNervous system disorders11/250/240/2832/8535/85
Neutrophil count decreasedInvestigations10/251/240/2837/8531/85
Platelet count decreasedInvestigations7/250/241/2834/8518/85
Decreased appetiteMetabolism and nutrition disorders10/254/244/2830/8526/85
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders10/250/240/2817/8517/85

Baseline characteristics

Parts A \& B planned for 72 subjects enrolled: 25 subjects enrolled in Part A, 53 subjects enrolled in Part B. The Safety population consisted of 25 subjects in Part A, 52 subjects in Part B; the modified Intent-to-Treat population consisted of 22 subjects in Part A, 52 patients in Part B. Part C planned for 160 subjects enrolled: 170 subjects were randomized, with 84 treated subjects in the experimental group, 85 treated subjects in the control group.

Age, Categorical
Age, Categorical(Participants)Part A First Line TreatmentPart B1 Second Line TreatmentPart B2 Second Line TreatmentPart C Control First Line TreatmentPart C Experimental First Line TreatmentTotal
<=18 years000000
Between 18 and 65 years1615165057154
>=65 years9912352893
Age, Continuous
Age, Continuous(years)Part A First Line TreatmentPart B1 Second Line TreatmentPart B2 Second Line TreatmentPart C Control First Line TreatmentPart C Experimental First Line TreatmentTotal
Mean58.6 ± 14.6559.0 ± 7.9460.0 ± 13.7059.8 ± 12.7659.0 ± 11.3959.4 ± 12.15
Sex: Female, Male
Sex: Female, Male(Participants)Part A First Line TreatmentPart B1 Second Line TreatmentPart B2 Second Line TreatmentPart C Control First Line TreatmentPart C Experimental First Line TreatmentTotal
Female647212664
Male1920216459183
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A First Line TreatmentPart B1 Second Line TreatmentPart B2 Second Line TreatmentPart C Control First Line TreatmentPart C Experimental First Line TreatmentTotal
Hispanic or Latino3215112
Not Hispanic or Latino2222268082232
Unknown or Not Reported001023
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A First Line TreatmentPart B1 Second Line TreatmentPart B2 Second Line TreatmentPart C Control First Line TreatmentPart C Experimental First Line TreatmentTotal
American Indian or Alaska Native000000
Asian114185451138
Native Hawaiian or Other Pacific Islander100001
Black or African American100023
White2099283096
More than one race000011
Unknown or Not Reported211318
Region of Enrollment
Region of Enrollment(Participants)Part A First Line TreatmentPart B1 Second Line TreatmentPart B2 Second Line TreatmentPart C Control First Line TreatmentPart C Experimental First Line TreatmentTotal
South Korea014165149130
United States2510123030107
Germany0004610
Body Surface Area (BSA)
Body Surface Area (BSA)(m^2)Part A First Line TreatmentPart B1 Second Line TreatmentPart B2 Second Line TreatmentPart C Control First Line TreatmentPart C Experimental First Line TreatmentTotal
Mean2.0 ± 0.231.8 ± 0.251.8 ± 0.261.8 ± 0.251.8 ± 0.281.8 ± 0.27
08

Study locations

48 sites
  • Mayo Clinic Cancer Center
    Phoenix, Arizona 85054, United States
  • University of Arizona
    Tucson, Arizona 85724, United States
  • City of Hope
    Duarte, California 91010, United States
  • The Angeles Clinic Research Institute - A Cedars-Sinai Affiliate
    Los Angeles, California 90025, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • UCLA
    Los Angeles, California 90095, United States
  • Hoag Memorial Hospital Presbyterian
    Newport Beach, California 92663, United States
  • Chao Family Comprehensive Cancer Center, University of California, Irvine
    Orange, California 92868, United States
  • University of California San Francisco
    San Francisco, California 94158, United States
  • Mayo Clinic Florida
    Jacksonville, Florida 32224, United States
  • AdventHealth Cancer Institute
    Orlando, Florida 32804, United States
  • Northwestern University Robert H. Lurie Comprehensive Cancer Center
    Chicago, Illinois 60611, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Pontchartrain Cancer Center
    Covington, Louisiana 70433, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Wisconsin Carbone Cancer Center
    Madison, Wisconsin 53792, United States
  • Charité Universitätsmedizin Berlin
    Berlin, 13353, Germany
  • Institut Fur Klinisch Onkologische Forschung Am Krankenhaus Nordwest
    Frankfurt, 60488, Germany
  • Hämatologisch-Onkologische Praxis Eppendorf (HOPE)
    Hamburg, 20249, Germany
  • Universitatsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Slk-Kliniken
    Heilbronn, 74078, Germany
  • Studienzentrum Onkologie Ravensburg
    Ravensburg, 88212, Germany
  • Caritas Klinikum Saarbrücken St. Theresia
    Saarbrücken, 66113, Germany
  • CHA Bundang Medical Center
    Seongnam-si, Gyeonggi-do 13520, South Korea
  • Korea University Ansan Hospital
    Ansan-si, 15355, South Korea
  • Hallym University Sacred Heart Hospital
    Anyang, 14068, South Korea
  • Dong-A University Hospital
    Busan, 49201, South Korea
  • National Cancer Center
    Goyang, 10408, South Korea
  • Gachon University Gil Medical Center
    Incheon, 21565, South Korea
  • Inha University Hospital
    Incheon, 22332, South Korea
  • Seoul National University Bundang Hospital
    Seongnam, 13620, South Korea
  • Korea University Anam Hospital
    Seoul, 02841, South Korea
  • Hanyang University Hospital
    Seoul, 04763, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Boramae Hospital SNU
    Seoul, 07061, South Korea
  • Korea University Guro Hospital
    Seoul, 08308, South Korea
  • Seoul National University Hospital
    Seoul, 3080, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, 3722, South Korea
  • Samsung Medical Center
    Seoul, 6351, South Korea
  • The Catholic University of Korea St. Mary's Hospital
    Seoul, 6591, South Korea
  • The Catholic University of Korea St. Vincent's Hospital
    Suwon, 16247, South Korea
09

References and documents

Publications

  • Rha SY, Ryu MH, Kim JG, Xu S, Xu Y, Lee KW. Comparative efficacy of tislelizumab + FOLFOX or CAPOX for gastric/gastroesophageal junction adenocarcinoma: an exploratory matching-adjusted indirect comparison. Curr Med Res Opin. 2026 May;42(5):1031-1041. doi: 10.1080/03007995.2026.2686048. Epub 2026 Jun 29. PubMed 42371751 ↗
  • Yu J, Mehta R. Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma. J Natl Compr Canc Netw. 2025 May;23(5):e257036. doi: 10.6004/jnccn.2025.7036. PubMed 40341124 ↗
  • Klempner SJ, Sonbol MB, Wainberg ZA, Uronis HE, Chiu VK, Scott AJ, Iqbal S, Tejani MA, Chung V, Stilian MC, Thoma M, Zhang Y, Kagey MH, Baum J, Sirard CA, Altura RA, Ajani JA. DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish. J Clin Oncol. 2025 Jan 20;43(3):339-349. doi: 10.1200/JCO.24.00410. Epub 2024 Oct 21. PubMed 39432867 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Mar 2025, 56 months.

Results were first posted in Oct 2025, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2020
First posted
Apr 27, 2020
StartActual
Jul 29, 2020
Primary completionActual
Mar 31, 2025
CompletionActual
Mar 31, 2025
Results first posted
Oct 9, 2025
Last update
Oct 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04363801
Lead sponsor
Leap Therapeutics, Inc.
Collaborators
BeiGene
Responsible party
Sponsor
First posted
Apr 27, 2020
Start date
Jul 29, 2020
Primary completion
Mar 31, 2025
Completion
Mar 31, 2025
Results posted
Oct 9, 2025
Last update
Oct 9, 2025

Study contacts

Cynthia Sirard, MD
study director · Chief Medical Officer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sirexatamab · Tislelizumab

Start the discussion